Uses and limitations of randomization-based efficacy estimators

White, Ian R.
August 2005
Statistical Methods in Medical Research;Aug2005, Vol. 14 Issue 4, p327
Academic Journal
journal article
In randomized trials with departures from allocated treatment, intention-to-treat analysis is important but not always sufficient. The most common supplement to intention-to-treat analysis is per-protocol analysis, whose assumption of comparability between different nonrandomized groups is often implausible. Randomization-based methods avoid making this assumption and are preferable. Situations where intention-to-treat analysis is insufficient and a randomization-based method is useful include provision of patient information, exploration of treatment-covariate and treatment-time interactions, meta-analysis, and equivalence trials.


Related Articles

  • The Quality of Registration of Clinical Trials. Viergever, Roderik F.; Ghersi, Davina // PLoS Clinical Trials;Feb2011, Vol. 8 Issue 2, Special section p1 

    Background: Lack of transparency in clinical trial conduct, publication bias and selective reporting bias are still important problems in medical research. Through clinical trials registration, it should be possible to take steps towards resolving some of these problems. However, previous...

  • Trial results: the next battle. Abbasi, Kamran // BMJ: British Medical Journal (International Edition);1/15/2005, Vol. 330 Issue 7483, precedes p. 103 p103 

    Presents comments on an announcement by drug companies that results of clinical trials for drugs may soon become available to the public. Concerns about prescription drugs and their possible harmful effects; Assertion that unless the proposal to release clinical trial results is mandatory it...

  • Calendar of Events.  // Applied Clinical Trials;Jun2004, Vol. 13 Issue 6, p104 

    This article presents information on various events related to clinical trials to be held in several countries. Conference on Project Management for Clinical Trials will be held in Irvine, California on June 1-2, 2004. Conference titled "Monitoring Clinical Drug Studies: Beginner," will be held...

  • Patient study explores trial results question.  // European Pharmaceutical Executive;May/Jun2006, p14 

    The article reports that Taxotere as Adjuvant ChemoTherapy (TACT) has explored the question of if and how patients should be told of the results of clinical trials in which they participate. TACT's study revealed that posting results directly to patients' homes was preferred and that most of the...

  • Trials shock fuels public interest.  // European Pharmaceutical Executive;May/Jun2006, p16 

    The article reports on how the Parexel clinical trial elicited a surge of interested volunteers from the general public. Enter Trials is a web site through which patients can register to participate in clinical trials. It reported that after the Parexel incident, its server hits rose from...

  • MADNESS IN THEIR METHOD. Wade, Nicholas // New Republic;6/27/83, Vol. 188 Issue 25, p13 

    Focuses on issues concerning fraud in American scientific institutions. Fabrication of a data on new drugs by Joseph H. Cort, a researcher trained at Harvard and Yale Universities; Release of a report of an inquiry by the National Institutes of Health, into a major research fraud at the Harvard...

  • Experts emphasize need for speed in launch of Australian trials. Morgan, Branwen // Nature Medicine;May2011, Vol. 17 Issue 5, p521 

    The article reports on the need for a faster launch in conducting clinical trials of drugs in Australia. It mentions that the number of new trials recorded in the country has decreased to 574 due to higher operating costs and competition from the emerging countries. To address the issue, it...

  • Novartis to begin ADHD study in girls.  // PharmaWatch: CNS;October 2003, Vol. 2 Issue 10, p12 

    Reports on the commencement of a new clinical study to evaluate the efficacy and safety of Ritalin LA extended release capsules in girls aged 12 to 17 years old with attention-deficit/hyperactivity disorder (ADHD). Study design; Objective of the study; Potential impact of the study in the...

  • DOV shows positive phase III results for bicifadine.  // PharmaWatch: CNS;October 2003, Vol. 2 Issue 10, p14 

    Presents results of a phase III clinical trial of non-narcotic analgesic bicifadine. Indication of bicifadine; Efficacy of bicifadine as an analgesic; Demonstration of the analgesic effects of bicifadine in a well accepted clinical pain procedure.

  • Why are clinical costs so high? Frantz, Simon // Nature Reviews Drug Discovery;Nov2003, Vol. 2 Issue 11, p851 

    Discusses the rise in the costs of clinical development in the U.S. Large increase in the cost of clinical development compared to preclinical costs which has made them the most expensive aspect of drug development; Suggestion of Joseph DiMasi, Director of Economic Analysis at the Tufts Center...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics